Literature DB >> 18297705

Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma.

Yuehua Huang1, Zhanhui Wang, Shengli An, Bin Zhou, Yuanping Zhou, Henry Lik-Yuen Chan, Jinlin Hou.   

Abstract

Identification of risk factors for recurrence and metastasis of HCC is important for the prognosis of HCC surveillance in chronic HBV infection. In this article, 125 HCC patients recruited were followed up prospectively for tumor metastasis and recurrence for a median of 104 (10-130) weeks. HBV DNA level was detected by LightCycler-based real-time fluorescence quantitative polymerase chain reaction-restriction system. HBV genotypes were determined by using PCR restriction-fragment length polymorphism. BCP and PC mutations were performed by PCR and direct sequencing of amplified products. Among 125 HCC patients, 19 patients were excluded because of the lack of follow-up data and the remaining 106 patients were followed up of 2 years and entered into analysis. Sixty-nine patients had tumor metastasis or recurrence during the follow-up and the cumulative probability of HCC metastasis or recurrence was 65.1%. On multivariate analysis, genotype C and HBV DNA level were the risk factors for HCC recurrence or metastasis. The incidence of recurrence or metastasis increased with baseline HBV DNA level in a dose-response relationship ranging from 22% for HBV DNA level of less than 3 log10 copies/ml to 80% for HBV DNA level of 5 log10 copies/ml or greater (P = 0.012). Fifty-seven (74.0%) and 12 (41.4%) patients had metastasis or recurrence in patients with genotype C and B, respectively. The adjusted OR of recurrence or metastasis for genotype C compared with genotype B was 9.755 (P = 0.009). In conclusion, elevated HBV DNA level and genotype C are strong risk predictors of HCC metastasis or recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297705     DOI: 10.1002/jmv.21117

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

Review 1.  Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review.

Authors:  Jian-Hong Zhong; Qing-Lian Zhong; Le-Qun Li; Hang Li
Journal:  Tumour Biol       Date:  2014-08-14

Review 2.  Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection.

Authors:  Yang Ke; Lin Wang; Le-Qun Li; Jian-Hong Zhong
Journal:  World J Hepatol       Date:  2014-09-27

3.  Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.

Authors:  Yi-Fu He; Juan Jin; Wei Wei; Yan Chang; Bing Hu; Chu-Shu Ji; Wei-Dong Jia; Xiao-Qiu Wang; Ke Chen; Jian Chen
Journal:  Can J Gastroenterol       Date:  2010-07       Impact factor: 3.522

4.  Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study.

Authors:  Chunping Wang; Yinying Lu; Yan Chen; Yongyi Feng; Linjing An; Xinzhen Wang; Shuhui Su; Wenlin Bai; Lin Zhou; Yongping Yang; Dongping Xu
Journal:  Clin Exp Metastasis       Date:  2009       Impact factor: 5.150

5.  The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma.

Authors:  Makoto Chuma; Shuhei Hige; Toshiya Kamiyama; Takashi Meguro; Atsushi Nagasaka; Kazuaki Nakanishi; Yoshiya Yamamoto; Mitsuru Nakanishi; Toshihisa Kohara; Takuya Sho; Keiko Yamamoto; Hiromasa Horimoto; Tomoe Kobayashi; Hideki Yokoo; Michiaki Matsushita; Satoru Todo; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2009-06-25       Impact factor: 7.527

6.  The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis.

Authors:  Xu-Xiao Chen; Jian-Wen Cheng; Ao Huang; Xin Zhang; Jian Wang; Jia Fan; Jian Zhou; Xin-Rong Yang
Journal:  Onco Targets Ther       Date:  2017-11-10       Impact factor: 4.147

7.  Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy.

Authors:  Yin Zhu; Pei-Jing Cui; Jing Yao; Zheng-Yun Zhang; Jun Yang
Journal:  Gastroenterol Res Pract       Date:  2018-04-01       Impact factor: 2.260

8.  Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma.

Authors:  Pei-Song Bai; Nan Xia; Hong Sun; Ying Kong
Journal:  J Cell Mol Med       Date:  2017-05-30       Impact factor: 5.310

9.  The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection.

Authors:  Linye He; Zijing Xia; Junyi Shen; Xiaoyun Zhang; Wei Peng; Chuan Li; Tianfu Wen
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

10.  The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta-analysis.

Authors:  Zijing Xia; Linye He; Li Xiong; Tianfu Wen
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.